NA Proactive news snapshot: Kintara Therapeutics, PlantX Life, Binovi Technologies, Atlas Engineered Products, ImagineAR UPDATE ... Analysts at Aegis Capital Corp rated Kintara Therapeutics Inc (NASDAQ:KTRA) a ''Buy,'' while maintaining a $7 share target price on the company which develops new solid tumor cancer therapies. The San Diego, California-based clinical stage drug development company closed its fiscal third quarter with cash and equivalents of about $15.7 million. In a note to clients, Aegis Capital analysts said that Kintaras financial runway had been extended. The company stated that its available cash would be sufficient to fund operations through 2Q22 (formerly 4Q21), with warrant exercise and Adgero synergies making up the delta, said Aegis Capital analyst Nathan Weinstein. PlantX Life Inc (CSE:VEGA) (OTCQB:PLXTF) (FRA:WNT1) announced the launch of its new PlantX warehouse in Squamish, British Columbia. PlantX said the new warehouse is a critical component of the company''s expansion plans and will be used to support its supply chain for the distribution of indoor plants across Canada. Binovi Technologies Corp (CVE:VISN) (OTCQB:BNVIF) says neuro-visual performance platform Binovi Connect stepping up to serve a wider market.